Sensile Medical develops innovative drug delivery products and platforms, including digital connected capabilities.

It is already working highly successfully with customers on the development of devices for diabetics and patients with heart complaints. Depending on the attainment of contractually specified milestones, the purchase price will be a maximum of EUR 350m. The initial payment is EUR 175m. Independently of this, Gerresheimer has secured two new major contracts: one for the manufacture of inhalers and another for prefillable syringes for a major heparin producer.

At the same time, Gerresheimer has lost a significantly smaller order in the inhaler business resulting in a restructuring that will affect the plant in KĂŒssnacht, Switzerland, which is to be closed by the end of 2019.

As a result and excluding Sensile Medical, there are changes in the planning of capital expenditures, profitability and revenues.

For the years 2019 and 2020, capital expenditures are expected to be higher by two to a maximum of four percentage points of revenues at constant exchange rates, among other things for the capacity expansion at the plant in Horsovsky Tyn, Czech Republic; further automation; and a new plant in Eastern Europe.

At the same time, Gerresheimer anticipates that this will lead in 2019 and 2020 to an approximately one-percentage-point reduction in the adjusted EBITDA margin (relative to the financial year 2017) as a consequence of low-margin revenues in the engineering and tooling business for the new major orders and of increased expenditures for relocation, employee training and production start-up/ramp-up.

In the years 2021 and 2022, Gerresheimer expects—again, excluding Sensile Medical—that both revenues and the adjusted EBITDA margin will increase by two percentage points beyond the usual rate of growth while capital expenditures will return to around 8%.

"All rights reserved except agreement written by Emballage Digest or mention of the magazine''